Observational Study of the Heart Repair Technologies Mitral Bridge in Treating Mitral Valve Regurgitation

Mitral Regurgitation Clinical Trial

— HRT  

Official title:

HRT Observational Study of a Mitral Bridge in Patients With Moderate to Severe Mitral Valve Regurgitation to Evaluate Device Safety and Performance

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03511716
• Other study ID #: HRT Mitral Bridge
• Status: Terminated
• Start date: February 6, 2014
• Est. completion date: August 31, 2019

Study information

• Verified date: August 2019
• Source: Heart Repair Technologies, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Prospective, observational, multi-center trial in which patients with mitral regurgitation sufficient to merit mitral valve repair will receive a surgical transvalvular, intra-annular Mitral Bridge™ to reduce or eliminate mitral regurgitation.

Description:

The primary objective of this study is to evaluate the safety and performance of the Mitral Bridge device in the correction of mitral valve regurgitation in patients who qualify for mitral valve repair as defined by the American Society of Echocardiography (ASE). The device is a single use, mitral valve implant designed to reduce mitral regurgitation by reducing the septo-lateral mitral annular diameter, promoting early coaptation of the valve leaflets and restraining the leaflets below the intra-annular plane.

The protocol was designed as a First In Man (FIM) with a 6-month follow up but was amended to follow the enrolled patients for a total of 5 years.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 34
• Est. completion date: August 31, 2019
• Est. primary completion date: August 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Patients moderate to severe, symptomatic functional (ischemic or dilated cardiomyopathies) mitral regurgitation or mitral regurgitation caused by dilation of the mitral annulus who qualify for mitral valve repair with cardiopulmonary bypass

• Mitral regurgitation must meet the following criteria:

• The primary regurgitant jet is central, originating from mal coaptation of anterior and posterior leaflets of the mitral valve.

• If a secondary jet is present, the jet must be considered clinically insignificant.

• Women of child-bearing potential have a negative pregnancy test

Exclusion Criteria:

• Evidence of severe mitral annular and leaflet calcification.

• Patient is hemodynamically unstable.

• Patient has hypertrophic cardiomyopathy and has systolic anterior motion of the leaflets.

• Patient requires emergency surgery.

• Patient has echocardiographic evidence of endocarditis or rheumatic heart disease.

• Transesophageal Echocardiogram (TEE) is contraindicated or cannot be performed intraoperatively for any reason.

• Patient has known chronic, dialysis-dependent renal failure.

• History of stroke, transient ischemic attack (TIA) or reversible ischemic neurological disease within the last three (3) months.

• History of gastrointestinal bleeding within the last three (3) months.

• History of hypersensitivity or allergy to aspirin

• History or hypersensitivity to clopidogrel (Plavix) or its congeners.

• Active or treated malignancies in the last twelve (12) months.

• Patient is participating in another clinical study for which follow-up is currently ongoing.

• Women of child-bearing age who have not had a negative pregnancy test.

• Patient with non-cardiac co-morbidities and life expectancy < 1 year.

• Patient has a condition that, in the opinion of the Investigator, precludes participation, including willingness to comply with all follow-up procedures.

Related Conditions & MeSH terms

• Mitral Regurgitation
• Mitral Valve Insufficiency

Intervention

Device:
• HRT Mitral Bridge Mitral Valve Repair
Surgical mitral valve implant intended to reduce mitral regurgitation by direct reduction of the septo-lateral mitral annular diameter, promoting early coaptation of the valve leaflets and restraining the leaflets below the intra-annular plane

Locations

Country	Name	City	State
Czechia	Na Homolce Hospital	Prague	Homolka

Sponsors (2)

Lead Sponsor	Collaborator
Heart Repair Technologies, Inc.	Na Homolce Hospital

Country where clinical trial is conducted

Czechia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical Success	- Freedom from subsequent open mitral valve repair or replacement	One, 3, 6,12, 24, 36, 48, and 60 months
Secondary	Preservation or improvement of left ventricular remodeling	Change in Left Ventricular status	One, 3, 6,12, 24, 36, 48, and 60 months
Secondary	Preservation of improvement in NYHA (New York Heart Association) functional class.	Change in NYHA (New York Heart Association) functional class.	One, 3, 6,12, 24, 36, 48, and 60 months